Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2B Study of Pegbelfermin (BMS-986036) in Adults With NASH and Stage 3 Liver Fibrosis
jRCT2080223975Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis comparing Pegbelfermin arm with Placebo arm (2 arms). Started Jul 2018; status: completed.
02
Drugs
pegbelfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on jRCT2080223975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223975.